Sun Young Kim1, Ji Sung Lee2, Junho Kang1, Satoshi Morita3, Young Suk Park4, Junichi Sakamoto5, Kei Muro6, Rui-Hua Xu7, Tae Won Kim1. 1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 2. Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 3. Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 4. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 5. Tokai Central Hospital, Kakamigahara, Japan. 6. Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. 7. Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Abstract
BACKGROUND: Concomitant use of proton pump inhibitors (PPIs) with capecitabine was suggested to be associated with poor outcomes in gastrointestinal cancers. We analyzed the differential impact of PPI use on capecitabine and fluorouracil using the data set from the AXEPT trial, a phase III randomized trial that demonstrated the noninferiority of mXELIRI (modified XELIRI: capecitabine plus irinotecan) to FOLFIRI (leucovorin, fluorouracil, and irinotecan), either with or without bevacizumab in patients with metastatic colorectal cancer. PATIENTS AND METHODS: Out of the per-protocol set (n = 620), patients with information on concomitant medications (n = 482) were included in this post hoc analysis. PPI use was defined as concomitant exposure of capecitabine and the use of any PPI for 20% or more of the study period. The treatment-by-PPI-use interaction was examined after adjusting for stratification factors. RESULTS: Of the 482 patients, 49 (10.1%) used PPI. Among the PPI users, the mXELIRI group tended to have poorer overall survival compared with the FOLFIRI group. In contrast, among the nonusers, the overall survival of the mXELIRI group was significantly better than that of the FOLFIRI group. Similarly, a trend of worse progression-free survival with mXELIRI compared with FOLFIRI was observed in PPI users but not in nonusers. Treatment-by-PPI-use interaction was significant for overall survival and progression-free survival. CONCLUSION: The significant interaction between PPI use and the type of fluoropyrimidine in terms of overall and progression-free survival suggests that fluorouracil could be a more favorable option than capecitabine for patients with metastatic colorectal cancer using PPIs. IMPLICATIONS FOR PRACTICE: This study showed a significant interaction between the use of proton pump inhibitors (PPIs) and the type of fluoropyrimidines. This interaction mainly comes from the positive impact of PPIs in the survival outcomes in the fluorouracil arm rather than a negative impact of PPIs in the capecitabine arm. The possible drug-drug interaction shown in this study suggests that fluorouracil, rather than capecitabine, could be a more appropriate choice of fluoropyrimidine for patients who are taking PPIs in the treatment of metastatic colorectal cancer.
RCT Entities:
BACKGROUND: Concomitant use of proton pump inhibitors (PPIs) with capecitabine was suggested to be associated with poor outcomes in gastrointestinal cancers. We analyzed the differential impact of PPI use on capecitabine and fluorouracil using the data set from the AXEPT trial, a phase III randomized trial that demonstrated the noninferiority of mXELIRI (modified XELIRI: capecitabine plus irinotecan) to FOLFIRI (leucovorin, fluorouracil, and irinotecan), either with or without bevacizumab in patients with metastatic colorectal cancer. PATIENTS AND METHODS: Out of the per-protocol set (n = 620), patients with information on concomitant medications (n = 482) were included in this post hoc analysis. PPI use was defined as concomitant exposure of capecitabine and the use of any PPI for 20% or more of the study period. The treatment-by-PPI-use interaction was examined after adjusting for stratification factors. RESULTS: Of the 482 patients, 49 (10.1%) used PPI. Among the PPI users, the mXELIRI group tended to have poorer overall survival compared with the FOLFIRI group. In contrast, among the nonusers, the overall survival of the mXELIRI group was significantly better than that of the FOLFIRI group. Similarly, a trend of worse progression-free survival with mXELIRI compared with FOLFIRI was observed in PPI users but not in nonusers. Treatment-by-PPI-use interaction was significant for overall survival and progression-free survival. CONCLUSION: The significant interaction between PPI use and the type of fluoropyrimidine in terms of overall and progression-free survival suggests that fluorouracil could be a more favorable option than capecitabine for patients with metastatic colorectal cancer using PPIs. IMPLICATIONS FOR PRACTICE: This study showed a significant interaction between the use of proton pump inhibitors (PPIs) and the type of fluoropyrimidines. This interaction mainly comes from the positive impact of PPIs in the survival outcomes in the fluorouracil arm rather than a negative impact of PPIs in the capecitabine arm. The possible drug-drug interaction shown in this study suggests that fluorouracil, rather than capecitabine, could be a more appropriate choice of fluoropyrimidine for patients who are taking PPIs in the treatment of metastatic colorectal cancer.
Authors: Grace G Wong; Vincent Ha; Michael P Chu; Deonne Dersch-Mills; Sunita Ghosh; Carole R Chambers; Michael B Sawyer Journal: Clin Colorectal Cancer Date: 2018-11-16 Impact factor: 4.481
Authors: B Reigner; S Clive; J Cassidy; D Jodrell; R Schulz; T Goggin; L Banken; B Roos; M Utoh; T Mulligan; E Weidekamm Journal: Cancer Chemother Pharmacol Date: 1999 Impact factor: 3.333
Authors: Charles S Fuchs; John Marshall; Edith Mitchell; Rafal Wierzbicki; Vinod Ganju; Mark Jeffery; Joseph Schulz; Donald Richards; Raoudha Soufi-Mahjoubi; Benjamin Wang; José Barrueco Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: Julia Sun; Alastair I Ilich; Christina A Kim; Michael P Chu; Grace G Wong; Sunita Ghosh; Melanie Danilak; Karen E Mulder; Jennifer L Spratlin; Carole R Chambers; Michael B Sawyer Journal: Clin Colorectal Cancer Date: 2015-12-28 Impact factor: 4.481
Authors: Michael P Chu; Sunita Ghosh; Carole R Chambers; Naveen Basappa; Charles A Butts; Quincy Chu; David Fenton; Anil A Joy; Randeep Sangha; Michael Smylie; Michael B Sawyer Journal: Clin Lung Cancer Date: 2014-08-15 Impact factor: 4.785
Authors: Michael P Chu; J Randolph Hecht; Dennis Slamon; Zev A Wainberg; Yung-Jue Bang; Paulo M Hoff; Alberto Sobrero; Shukui Qin; Karen Afenjar; Vincent Houe; Karen King; Sheryl Koski; Karen Mulder; Julie Price Hiller; Andrew Scarfe; Jennifer Spratlin; Yingjie J Huang; Saba Khan-Wasti; Neil Chua; Michael B Sawyer Journal: JAMA Oncol Date: 2017-06-01 Impact factor: 31.777